Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12382603 | 0.83 | ATM (0.42) | ATMWDR5MEN1HCRTR1KMT2A | |
| SCHEMBL2294983 | 0.83 | ATM (0.42) | ATMWDR5MEN1HCRTR1KMT2A | |
| SCHEMBL2295376 | 0.68 | ATM (0.46) | ATMMEN1HCRTR1KMT2ANTRK1 | |
| SCHEMBL12382598 | 0.68 | MEN1 (0.35) | MEN1KMT2ANTRK1 | |
| SCHEMBL18270526 | 0.67 | ATM (0.63) | ATMMEN1HCRTR1KMT2ADRD2 | |
| SCHEMBL12382614 | 0.67 | ATM (0.42) | ATMWDR5MEN1HCRTR1KMT2A | |
| SCHEMBL2297131 | 0.67 | ATM (0.42) | ATMWDR5MEN1HCRTR1KMT2A | |
| SCHEMBL21311185 | 0.67 | ATM (0.80) | ATMMEN1HCRTR1KMT2A | |
| SCHEMBL2293889 | 0.65 | MAOA (0.39) | MEN1KMT2ANTRK1 | |
| SCHEMBL12422969 | 0.65 | MAOA (0.39) | MEN1KMT2ANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | PTMS, APEX1, ALG1 | ATM 918/4885WDR5 3985/4885MEN1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.